On October 8, 2020 Seagen Inc. reported that it is the new corporate name for Seattle Genetics, Inc. (Nasdaq:SGEN), a global biotechnology company dedicated to developing innovative cancer medicines that make a meaningful difference in people’s lives around the world (Press release, Seattle Genetics, OCT 8, 2020, View Source [SID1234568232]). The evolution of the corporate name reflects the transformation of Seagen as it expands operations globally to bring its marketed medicines to more patients, pursues new indications for approved medicines and continues to advance its pipeline of novel therapies for solid tumors and blood-related cancers. The Company’s common stock will continue to trade under its current ticker symbol: "SGEN."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The change in our corporate name from Seattle Genetics to Seagen reflects who we are today, as we expand our presence beyond the Pacific Northwest and outside of the United States to support the commercialization of TUKYSA globally," said Clay Siegall , Ph.D., President and Chief Executive Officer of Seagen. "We have three marketed products and a robust development pipeline of novel targeted product candidates. As we increase our global presence by adding new team members and locations outside of the United States as well as through strategic partnerships, we are better positioned to bring important new therapies to cancer patients around the world. Our passion for helping patients is stronger than ever."

Seagen is focused on discovering safe and effective novel therapeutics to advance cancer care. As a pioneer in antibody-drug conjugates (ADCs), Seagen has been a leader in novel cancer therapeutics for more than 20 years. ADCETRIS (brentuximab vedotin) is approved in over 70 countries around the world and continues to make a difference in the lives of patients with several types of lymphomas. In the last year, Seagen successfully launched two new cancer medicines that address significant unmet medical needs. PADCEV (enfortumab vedotin) was the first antibody-drug conjugate (ADC) approved for locally advanced or metastatic urothelial (bladder) cancer following treatment with platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. TUKYSA (tucatinib) was approved in the U.S. for metastatic HER2-positive breast cancer following an expedited U.S. Food and Drug Administration (FDA) approval. TUKYSA has also received approval in Australia , Canada , Singapore and Switzerland under the Project Orbis initiative of the FDA Oncology Center of Excellence and is under review with the European Medicines Agency (EMA).

The company also recently entered into two strategic collaborations with Merck that will accelerate and broaden the global development of the investigational ADC ladiratuzumab vedotin and the commercialization of TUKYSA in Asia , the Middle East , Latin America and other regions outside of the U.S. , Canada and Europe . These strategic collaborations will further expand Seagen’s global presence in oncology and ability to deliver cancer medicines around the world.

Along with the new name, the company will adopt a new logo and will change its corporate website from www.seattlegenetics.com to www.seagen.com . Seagen will provide further updates to customers, suppliers and partners regarding these changes in the implementation of the new name.

On October 8, 2020 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported that its President and Chief Executive Officer, Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the BIO Investor Forum, held virtually October 13-15, 2020 (Press release, Soligenix, OCT 8, 2020, View Source [SID1234568233]). The presentation will be available on-demand for conference attendees.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 7, 2020 Brainlab, the digital medical technology company, reported the planned delivery of 10 new ExacTrac Dynamic systems to GenesisCare, offering US cancer patients and physicians access to the latest treatment technologies on the market (Press release, GenesisCare, OCT 7, 2020, View Source [SID1234568198]). This follows GenesisCare’s acquisition of major integrated cancer care provider, 21st Century Oncology, increasing access to advanced cancer care for patients across US communities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ExacTrac Dynamic, a patient positioning and position monitoring device, received FDA 510(k) clearance in July 2020 and supports the delivery of precision radiotherapy with surface and thermal tracking combined with real-time X-Ray monitoring. ExacTrac Dynamic will allow GenesisCare physicians to deliver stereotactic radiosurgery, a non-invasive form of radiation therapy which delivers precisely targeted radiation in fewer high-dose treatments than traditional therapies.

Australian-headquartered GenesisCare is one of the largest networks of integrated oncology care in the world, with treatment centers and clinics across Australia, the UK, Spain and now the US. ExacTrac Dynamic systems have already been rolled out in Australia and the UK, providing patients access to the latest advancements in radiation therapy, including stereotactic radiosurgery and tattoo-free treatment.

"During COVID-19, we have remained steadfastly committed to ensuring all cancer patients in local communities across the United States and globally receive rapid access to world-class cancer care. Our investment in these cutting-edge ExacTrac Dynamic systems will help us deliver on our vision to ensure as many cancer patients as possible are able to receive the right treatment, at the right time, closer to home. Our partnership with Brainlab will allow our physicians in the US to automate precise patient monitoring during the delivery of faster, more personalized radiotherapy treatments in our 290 centers across the country," said Dan Collins, Founder and Global Chief Executive Officer, GenesisCare."

Building upon the first generation ExacTrac X-Ray, the new ExacTrac Dynamic system expands clinical workflows beyond traditional stereotactic capabilities with new surface-guided and thermal technology. These high-precision tracking and verification capabilities enable the delivery of effective prescription target doses, with less radiation to normal healthy tissues, for a wide range of treatment locations in the body. The system allows for:

Surface guided patient setup without tattoos or markings
Submillimetric patient monitoring using integrated surface, thermal, and X-Ray imaging at all couch angles
Real-time motion management with automatic beam-hold enabling future applications such as Deep Inspiration Breath Hold (DIBH) gated treatments*
"It’s exciting for Brainlab to continue to work with GenesisCare as they expand their presence in the United States," said Stefan Vilsmeier, President and CEO, Brainlab. "We have long partnered with GenesisCare in Australia and the UK and share their vision to make precision radiotherapy more accessible on a global scale."

First deliveries are planned for November 2020.

On October 7, 2020 Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, reported the completion of a $28.5 million equity financing (Press release, Sensei Biotherapeutics, OCT 7, 2020, View Source [SID1234568267]). The financing was co-led by Cambrian Biopharma and H&S Ventures, along with participation from new investors Future Ventures, Christian Angermayer’s Apeiron Investment Group, and Presight Ventures, Apeiron’s U.S. arm.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sensei is currently advancing multiple clinical and pre-clinical studies with their lead Immunophage program, SNS-301, a bacteriophage engineered to express aspartate β-hydroxylase (ASPH), a tumor associated antigen. The proceeds from the Series AA financing will enable the further development of SNS-301 and enable the advancement of Sensei’s pipeline of novel immunotherapies based on its Immunophage platform, which combines a vaccine’s ability to generate antigen-specific B- and T-cells with payloads of immunomodulatory nanobodies. Sensei Bio is building an extensive R&D infrastructure for the discovery of Immunophage, including GMP manufacturing, and is creating libraries of Immunophage that will be combined to create personalized yet off the shelf cocktails based on the genetic profile of each patient’s tumor.

"With this new funding, we advance our vision for establishing a new and disruptive class of immunotherapies called Immunophage, based on engineered bacteriophage," said John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics. "We are poised for significant progress as this funding enables us to expand our clinical programs for SNS-301 and operate our Immunophage platform at scale. We are grateful for the support from both new and existing investors and I look forward to further realizing Sensei’s potential and building out this new class of immunotherapies."

"Sensei’s phage platform represents a transformative leap in immuno-oncology, with a cancer vaccine that can induce all the elements of a robust anti-tumor immune response. With experienced management and scientific teams, Sensei is well positioned to become a leader in next generation of immune-oncology therapeutics," said James Peyer, CEO of Cambrian Biopharma. "We are pleased to support their highly unique platform approach and advance these therapies clinically."

In its next stage of growth, Sensei Bio will employ its proprietary platform to discover novel classes of cancer immunotherapies and advance lead candidates toward the clinic. These approaches include the following:

The development of select immunomodulatory nanobodies, camelid-based antibodies, that can be deployed as Immunophage payloads or stand-alone therapeutics.
The expansion of Sensei’s library based approach by engineering Immunophage targeting additional tumor associated antigens.
The deployment of customized yet off-the-shelf Immunophage cocktail therapies targeting tumor associated antigens, neoantigens, and virally-based cancer antigens.
A novel antibody-based approach to novel checkpoint inhibition and other methods of altering the tumor microenvironment toward anti-tumor immunity.
Potential expansion of its therapeutic area focus into infectious diseases based on partnerships with Pharma companies and government entities.

On October 7, 2020 Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) reported that the Company will be participating in the BIO Investor Forum Digital, which is taking place virtually from October 13-15, 2020 (Press release, Oncolytics Biotech, OCT 7, 2020, View Source [SID1234568182]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company’s profile for the forum is available here. Registered attendees will be able to view an on-demand corporate overview provided by President and Chief Executive Officer Dr. Matt Coffey. Company management will also be participating in one-on-one investor meetings at the forum. To schedule a meeting, please submit a meeting request on the forum website, or email [email protected].